Forma Therapeutics Holdings (Forma Therapeutics Holdings) Total Current Liabilities : $33.46 Mil (As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Forma Therapeutics Holdings Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Forma Therapeutics Holdings's total current liabilities for the quarter that ended in Jun. 2022 was $33.46

Forma Therapeutics Holdings Total Current Liabilities Historical Data

The historical data trend for Forma Therapeutics Holdings's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forma Therapeutics Holdings Total Current Liabilities Chart

Forma Therapeutics Holdings Annual Data

Trend Dec18 Dec19 Dec20 Dec21

Total Current Liabilities

233.71 24.87 31.70 35.09

Forma Therapeutics Holdings Quarterly Data

Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22

Total Current Liabilities Get a 7-Day Free Trial 31.10 32.63 35.09 26.34 33.46

Forma Therapeutics Holdings Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Forma Therapeutics Holdings's Total Current Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 19.991 + 5.125

+ Other Current Liabilities + Current Deferred Liabilities

= 9.972 + 0

= 35.09

Forma Therapeutics Holdings's Total Current Liabilities for the quarter that ended in Jun. 2022 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 19.52 + 5.335

+ Other Current Liabilities + Current Deferred Liabilities

= 8.609 + 0

= 33.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Forma Therapeutics Holdings Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Forma Therapeutics Holdings's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forma Therapeutics Holdings Inc (NAS:FMTX) » Definitions » Total Current Liabilities

Comparable Companies

EIGR PGEN ALPN MCRB ACIU THRX XERS GBIO EWTX RANI OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122

Traded in Other Exchanges

N/A

Address

300 North Beacon Street, Suite 501, Watertown, MA, USA, 02472

Website

https://www.formatherapeutics.com

Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are Etavopivat, FT-7051, FT-8225, and others.

Executives

Agustin Melian officer: EVP, Research & Development C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142

Brian Andrew Lesser officer: SVP, Commercial Officer C/O FORMA THERAPEUTICS HOLDINGS, INC. 300 NORTH BEACON STREET SUITE 501 WATERTOWN MA 02472

Mary E. Wadlinger officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472

Jeannette Potts officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472

Frank D. Lee director, officer: President and CEO C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472

David N Cook officer: SVP, Chief Scientific Officer

Patrick F. Kelly officer: SVP, Chief Medical Officer C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472

Todd Shegog officer: SVP, Chief Financial Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139

Arturo Md Molina director 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024

John E Bishop officer: Chief Technology Officer 675 WEST KENDALL STREET, CAMBRIDGE MA 02142

Vickers Selwyn M Md director 600 NORTH 18TH STREET, BIRMINGHAM AL 35203

Thomas G Wiggans director

Frederick Wayne A.i. director 500 W MAIN ST., LOUISVILLE KY 40202

Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Headlines

From GuruFocus

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FMTX, TRQ, RMO
By PRNewswire PRNewswire • 09-01-2022

SHAREHOLDER ALERT: Weiss Law Investigates Forma Therapeutics Holdings, Inc.
By PRNewswire PRNewswire • 09-01-2022

Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
By Business Wire Business Wire • 09-01-2022

Forma Therapeutics to Participate in Upcoming Investor Conferences
By Business Wire Business Wire • 09-17-2021

Forma Therapeutics Announces Appointment of New Executive Team Members
By Business Wire Business Wire • 06-30-2022

Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
By Business Wire Business Wire • 11-30-2021

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Forma Therapeutics, Holdings Inc. (Nasdaq - FMTX), Professional Holding Corp. (Nasdaq � PFHD), CyberOptics Corporation (Nasdaq � CYBE), EVO Payments, Inc. (Nasdaq �
By Ds*** Ds*** • 09-01-2022

Thinking about investing in Forma Therapeutics, Jianzhi Century, Okta, Formula One, or Terra Classic?
By PRNewswire PRNewswire • 09-01-2022

Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference
By Business Wire Business Wire • 02-08-2022

Forma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
By Business Wire Business Wire • 03-01-2022

Forma Therapeutics Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Total Current Liabilities	Get a 7-Day Free Trial										31.10	32.63	35.09	26.34	33.46

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	19.991	+	5.125
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	9.972	+	0
	=	35.09

Agustin Melian	officer: EVP, Research & Development	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Brian Andrew Lesser	officer: SVP, Commercial Officer	C/O FORMA THERAPEUTICS HOLDINGS, INC. 300 NORTH BEACON STREET SUITE 501 WATERTOWN MA 02472
Mary E. Wadlinger	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Jeannette Potts	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Frank D. Lee	director, officer: President and CEO	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
David N Cook	officer: SVP, Chief Scientific Officer
Patrick F. Kelly	officer: SVP, Chief Medical Officer	C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Todd Shegog	officer: SVP, Chief Financial Officer	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Arturo Md Molina	director	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
John E Bishop	officer: Chief Technology Officer	675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Vickers Selwyn M Md	director	600 NORTH 18TH STREET, BIRMINGHAM AL 35203
Thomas G Wiggans	director
Frederick Wayne A.i.	director	500 W MAIN ST., LOUISVILLE KY 40202
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116